Eli Lilly Earnings Call Recap: Stock Tanks on Weight Loss Pill Miss
Update: 2025-08-07
Description
Zepbound now leads two-thirds of the U.S. obesity market—and that’s just the beginning. In this video, we break down the biggest headlines from Eli Lilly’s latest earnings call, including:
✅ Over 1 million Zepbound vials prescribed in Q2
✅ New Phase 3 tirzepatide trial for type 1 diabetes
✅ 39% reduction in all-cause mortality (MACE-3)
✅ Orforglipron data and pricing strategy revealed
✅ Retatrutide and the future of complex obesity care
✅ Employer coverage shifts and LillyDirect updates
✅ The real reason behind Lilly’s compounding crackdown
✅ How Canadian generics might replace U.S. compounders
🎯 Whether you’re on GLP-1 meds or just trying to get answers in a system that keeps moving the goalposts, this episode is for you.
✅ Over 1 million Zepbound vials prescribed in Q2
✅ New Phase 3 tirzepatide trial for type 1 diabetes
✅ 39% reduction in all-cause mortality (MACE-3)
✅ Orforglipron data and pricing strategy revealed
✅ Retatrutide and the future of complex obesity care
✅ Employer coverage shifts and LillyDirect updates
✅ The real reason behind Lilly’s compounding crackdown
✅ How Canadian generics might replace U.S. compounders
🎯 Whether you’re on GLP-1 meds or just trying to get answers in a system that keeps moving the goalposts, this episode is for you.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
